Clinical Laserthermia Systems AB (publ) (CLS-B.ST)
SEK 3.84
(-2.04%)
SEK 3.84
(-2.04%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -68.4 Million SEK | -9.19% |
| 2022 | -57.84 Million SEK | -5.22% |
| 2021 | -57.05 Million SEK | -6.46% |
| 2020 | -51.61 Million SEK | -30.93% |
| 2019 | -39.41 Million SEK | -21.09% |
| 2018 | -32.55 Million SEK | -54.84% |
| 2017 | -21.02 Million SEK | 21.83% |
| 2016 | -26.89 Million SEK | -62.6% |
| 2015 | -16.54 Million SEK | 6.78% |
| 2014 | -17.74 Million SEK | 1.57% |
| 2013 | -18.02 Million SEK | -43.51% |
| 2012 | -12.56 Million SEK | -80.99% |
| 2011 | -6.94 Million SEK | -43.5% |
| 2010 | -4.85 Million SEK | -161.06% |
| 2009 | -1.85 Million SEK | -225.5% |
| 2008 | -569.15 Thousand SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -12.26 Million SEK | -8.44% |
| 2024 Q1 | -16.38 Million SEK | 51.88% |
| 2024 Q3 | -11.97 Million SEK | 7.63% |
| 2023 Q1 | -14.49 Million SEK | -22685.43% |
| 2023 Q4 | -19.41 Million SEK | -29.96% |
| 2023 Q2 | -16.36 Million SEK | -12.86% |
| 2023 FY | - SEK | -9.19% |
| 2023 Q3 | -14.93 Million SEK | 8.72% |
| 2022 Q4 | -63.62 Thousand SEK | 99.76% |
| 2022 Q1 | -13.28 Million SEK | 23.91% |
| 2022 Q2 | -18.09 Million SEK | -36.23% |
| 2022 FY | - SEK | -5.22% |
| 2022 Q3 | -26.37 Million SEK | -45.81% |
| 2021 Q1 | -7.66 Million SEK | 42.65% |
| 2021 Q3 | -11.32 Million SEK | 41.76% |
| 2021 Q4 | -17.45 Million SEK | -54.14% |
| 2021 FY | - SEK | -6.46% |
| 2021 Q2 | -19.44 Million SEK | -153.59% |
| 2020 Q4 | -13.36 Million SEK | -65.13% |
| 2020 Q2 | -9.7 Million SEK | 48.01% |
| 2020 FY | - SEK | -30.93% |
| 2020 Q1 | -18.66 Million SEK | -40.78% |
| 2020 Q3 | -8.09 Million SEK | 16.58% |
| 2019 Q4 | -13.25 Million SEK | -73.87% |
| 2019 FY | - SEK | -21.09% |
| 2019 Q3 | -7.62 Million SEK | 21.58% |
| 2019 Q1 | -8.8 Million SEK | 6.27% |
| 2019 Q2 | -9.72 Million SEK | -10.41% |
| 2018 FY | - SEK | -54.84% |
| 2018 Q1 | -869.72 Thousand SEK | 79.73% |
| 2018 Q4 | -9.39 Million SEK | -28.66% |
| 2018 Q3 | -7.3 Million SEK | 51.2% |
| 2018 Q2 | -14.96 Million SEK | -1620.86% |
| 2017 FY | - SEK | 21.83% |
| 2017 Q4 | -4.29 Million SEK | -19.17% |
| 2017 Q3 | -3.6 Million SEK | 31.08% |
| 2017 Q2 | -5.22 Million SEK | 32.28% |
| 2017 Q1 | -7.71 Million SEK | -61.31% |
| 2016 FY | - SEK | -62.6% |
| 2016 Q2 | -6.23 Million SEK | 22.85% |
| 2016 Q1 | -8.07 Million SEK | -77.84% |
| 2016 Q3 | -7.85 Million SEK | -26.11% |
| 2016 Q4 | -4.78 Million SEK | 39.13% |
| 2015 Q3 | -3.74 Million SEK | 0.8% |
| 2015 Q4 | -4.54 Million SEK | -21.27% |
| 2015 FY | - SEK | 6.78% |
| 2015 Q2 | -3.77 Million SEK | 15.57% |
| 2015 Q1 | -4.47 Million SEK | 48.26% |
| 2014 FY | - SEK | 1.57% |
| 2014 Q4 | -8.64 Million SEK | -179.53% |
| 2014 Q2 | -3.46 Million SEK | -36.36% |
| 2014 Q3 | -3.09 Million SEK | 10.74% |
| 2014 Q1 | -2.54 Million SEK | 58.66% |
| 2013 Q4 | -6.14 Million SEK | -55.44% |
| 2013 Q2 | -4.31 Million SEK | -19.1% |
| 2013 Q3 | -3.95 Million SEK | 8.31% |
| 2013 FY | - SEK | -43.51% |
| 2013 Q1 | -3.61 Million SEK | 4.34% |
| 2012 Q4 | -3.78 Million SEK | -26.95% |
| 2012 Q2 | -2.33 Million SEK | 30.79% |
| 2012 Q1 | -3.37 Million SEK | -37.09% |
| 2012 FY | - SEK | -80.99% |
| 2012 Q3 | -2.98 Million SEK | -27.41% |
| 2011 Q3 | -1.21 Million SEK | 24.97% |
| 2011 Q2 | -1.62 Million SEK | 0.13% |
| 2011 Q1 | -1.62 Million SEK | -49.96% |
| 2011 Q4 | -2.46 Million SEK | -102.27% |
| 2011 FY | - SEK | -43.5% |
| 2010 Q2 | -846.92 Thousand SEK | 54.0% |
| 2010 FY | - SEK | -161.06% |
| 2010 Q3 | -1.06 Million SEK | -25.59% |
| 2010 Q1 | -1.84 Million SEK | -551.26% |
| 2010 Q4 | -1.08 Million SEK | -1.99% |
| 2009 Q2 | -374.66 Thousand SEK | 54.88% |
| 2009 Q1 | -830.37 Thousand SEK | -254.56% |
| 2009 FY | - SEK | -225.5% |
| 2009 Q4 | -282.71 Thousand SEK | 22.52% |
| 2009 Q3 | -364.86 Thousand SEK | 2.62% |
| 2008 FY | - SEK | 0.0% |
| 2008 Q4 | 537.24 Thousand SEK | 244.23% |
| 2008 Q3 | -372.48 Thousand SEK | 18.57% |
| 2008 Q2 | -457.43 Thousand SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Acarix AB (publ) | -77.12 Million SEK | 11.302% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 116.607% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 116.607% |
| Arcoma AB | 6.24 Million SEK | 1194.846% |
| Bactiguard Holding AB (publ) | -89.98 Million SEK | 23.978% |
| BICO Group AB (publ) | 322.3 Million SEK | 121.224% |
| Boule Diagnostics AB (publ) | 65.97 Million SEK | 203.678% |
| CellaVision AB (publ) | 207.24 Million SEK | 133.007% |
| Chordate Medical Holding AB (publ) | -27.94 Million SEK | -144.806% |
| C-Rad AB (publ) | 48.9 Million SEK | 239.878% |
| Duearity AB (publ) | -24.77 Million SEK | -176.064% |
| Dignitana AB (publ) | -264 Thousand SEK | -25811.363% |
| Episurf Medical AB (publ) | -87.7 Million SEK | 22.0% |
| Getinge AB (publ) | 5.92 Billion SEK | 101.154% |
| Scandinavian Real Heart AB (Publ) | -67.25 Million SEK | -1.719% |
| Iconovo AB (publ) | -35.33 Million SEK | -93.59% |
| Integrum AB (publ) | 8.76 Million SEK | 880.754% |
| Luxbright AB (publ) | -23.86 Million SEK | -186.616% |
| Mentice AB (publ) | 28.87 Million SEK | 336.92% |
| OssDsign AB (publ) | -122.02 Million SEK | 43.939% |
| Paxman AB (publ) | 31.22 Million SEK | 319.046% |
| Promimic AB (publ) | -3.68 Million SEK | -1756.841% |
| Qlife Holding AB (publ) | -150.5 Million SEK | 54.549% |
| SciBase Holding AB (publ) | -51.82 Million SEK | -31.984% |
| ScandiDos AB (publ) | -13.35 Million SEK | -412.174% |
| Sectra AB (publ) | 615.06 Million SEK | 111.122% |
| Sedana Medical AB (publ) | -51.67 Million SEK | -32.38% |
| Senzime AB (publ) | -118.82 Million SEK | 42.43% |
| SpectraCure AB (publ) | -20.96 Million SEK | -226.224% |
| Stille AB | 56.04 Million SEK | 222.064% |
| Vitrolife AB (publ) | -3.18 Billion SEK | 97.852% |
| Xvivo Perfusion AB (publ) | 126.57 Million SEK | 154.044% |